SynCore Biotechnology (Taiwan) Performance
| 4192 Stock | TWD 35.50 0.30 0.84% |
The entity has a beta of -0.0314, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning SynCore Biotechnology are expected to decrease at a much lower rate. During the bear market, SynCore Biotechnology is likely to outperform the market. At this point, SynCore Biotechnology has a negative expected return of -0.18%. Please make sure to validate SynCore Biotechnology's jensen alpha, treynor ratio, and the relationship between the information ratio and total risk alpha , to decide if SynCore Biotechnology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days SynCore Biotechnology Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 539.2 M | |
| Total Cashflows From Investing Activities | -1.6 M |
SynCore |
SynCore Biotechnology Relative Risk vs. Return Landscape
If you would invest 3,995 in SynCore Biotechnology Co on September 5, 2024 and sell it today you would lose (445.00) from holding SynCore Biotechnology Co or give up 11.14% of portfolio value over 90 days. SynCore Biotechnology Co is generating negative expected returns and assumes 1.3744% volatility on return distribution over the 90 days horizon. Simply put, 12% of stocks are less volatile than SynCore, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
SynCore Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SynCore Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SynCore Biotechnology Co, and traders can use it to determine the average amount a SynCore Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1295
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 4192 |
Estimated Market Risk
| 1.37 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average SynCore Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SynCore Biotechnology by adding SynCore Biotechnology to a well-diversified portfolio.
SynCore Biotechnology Fundamentals Growth
SynCore Stock prices reflect investors' perceptions of the future prospects and financial health of SynCore Biotechnology, and SynCore Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SynCore Stock performance.
| Return On Equity | -0.43 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (13.97) % | |||
| Current Valuation | 2.86 B | |||
| Shares Outstanding | 115.08 M | |||
| Price To Book | 9.34 X | |||
| Price To Sales | 221.58 X | |||
| Revenue | 6.94 M | |||
| EBITDA | (404.13 M) | |||
| Cash And Equivalents | 380.81 M | |||
| Cash Per Share | 4.57 X | |||
| Total Debt | 61.11 M | |||
| Debt To Equity | 9.40 % | |||
| Book Value Per Share | 2.87 X | |||
| Cash Flow From Operations | (229.86 M) | |||
| Earnings Per Share | (3.73) X | |||
| Total Asset | 824.44 M | |||
About SynCore Biotechnology Performance
Evaluating SynCore Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if SynCore Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SynCore Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, dermatology, and infectious diseases in Taiwan and internationally. The company was founded in 2008 and is headquartered in Yilan, Taiwan. SYNCORE BIOTECHNOL operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 81 people.Things to note about SynCore Biotechnology performance evaluation
Checking the ongoing alerts about SynCore Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SynCore Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SynCore Biotechnology generated a negative expected return over the last 90 days | |
| The company reported the revenue of 6.94 M. Net Loss for the year was (458.6 M) with profit before overhead, payroll, taxes, and interest of 2.97 M. | |
| SynCore Biotechnology Co has accumulated about 380.81 M in cash with (229.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.57. | |
| Roughly 67.0% of the company shares are owned by insiders or employees |
- Analyzing SynCore Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SynCore Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining SynCore Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SynCore Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SynCore Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SynCore Biotechnology's stock. These opinions can provide insight into SynCore Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for SynCore Stock Analysis
When running SynCore Biotechnology's price analysis, check to measure SynCore Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynCore Biotechnology is operating at the current time. Most of SynCore Biotechnology's value examination focuses on studying past and present price action to predict the probability of SynCore Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynCore Biotechnology's price. Additionally, you may evaluate how the addition of SynCore Biotechnology to your portfolios can decrease your overall portfolio volatility.